RxDoctor Payments DataLook up a doctor →

Beverly Baxter

Acute Care · Little Rock, ARNPI 1356431837

Payments from drug & device makers

$95,213in general payments, 2019–2025

Across 434 payments — averaging $219.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$38K
  • Johnson & Johnson$20K
  • Amgen$16K
  • GSK$8K
  • Karyopharm Therapeutics Inc.$7K
  • Novartis$1K
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$2,5433%
  • Speaking & faculty fees$64,55368%
  • Travel & lodging$17,19118%
  • Food & beverage$10,33711%
  • Education$5891%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi63$37,567
Johnson & Johnson39$19,514
Amgen32$15,696
GSK16$7,811
Karyopharm Therapeutics Inc.14$6,541
Novartis73$1,117
Incyte Corporation17$701
Bristol Myers Squibb2$616
E.r. Squibb & Sons, L.L.C.5$390
Astellas Pharma US Inc10$389
Exelixis Inc.16$374
Merck15$331
Regeneron Healthcare Solutions, Inc.7$324
Daiichi Sankyo Inc.10$310
Mirati Therapeutics, Inc.7$275
Takeda Pharmaceuticals U.S.A., Inc.8$259
Pharmacyclics LLC, An Abbvie Company8$245
Beigene USA, Inc.11$243
AbbVie11$210
Beone Medicines USA, Inc.4$182
Eisai Inc.7$153
Pfizer7$143
Bayer1$124
AVEO Pharmaceuticals, Inc.4$120
Boehringer Ingelheim4$118
AstraZeneca(2 entities)4$116
EMD Serono, Inc.2$111
Myriad Genetic Laboratories, Inc.1$105
Genentech, Inc.1$103
Servier Pharmaceuticals LLC2$102
Gilead1$101
Sanofi-aventis U.S. LLC1$99
Adaptive Biotechnologies Corporation2$86
Alnylam Pharmaceuticals Inc.2$82
Pharmaessentia USA Corporation4$80
Epizyme, Inc.1$78
Genentech USA, Inc.4$75
Sobi, Inc3$64
Ipsen Biopharmaceuticals, Inc3$57
Lilly USA, LLC3$53
Pharmacosmos Therapeutics Inc.3$49
Viiv Healthcare Company2$34
Recordati_rare_diseases_inc.1$19
Tersera Therapeutics LLC1$15
Agios Pharmaceuticals, Inc.1$14
Stemline Therapeutics Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,213 in reported general payments places this provider in the 95th percentile of 321 acute care providers in Arkansas.

See all acute care providers in Arkansas →

Medicare billing

Part B allowed, 2024
$13,283
Medicare patients
40
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →